BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...

Acasunlimab is under clinical development by BioNTech and currently in Phase III for Non-Small Cell Lung Cancer.

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine ...

The BioNTech SE ADR BNTX inched 0.42% higher to $115.79 Friday, on what proved to be an all-around great trading session for ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...